| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
10 companies
Opaleye Management Inc. serves as a 10% Owner at OCUL and has filed Form 4s across 10 companies. Across recent SEC filings that breaks down to 278 buys and 109 sells. Those positions are worth an estimated $216.3M at current prices.
Historically, Opaleye Management Inc.'s trades have earned a middling insider score of 60/100 across 182 rated trades. Over a 12-month horizon, 44.4% of those trades were profitable, with an average 12-month return of +2.4%.
The biggest single holding is ETON (~$100.1M) as 10% Owner. The recent filings there lean toward selling, a net 1,175,715 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | GRCE Grace Therapeutics, Inc. | 10% Owner | Buy | 71,065 | $1.92 | $136,177.72 | +2.5% | |
| Oct 12, 2026 | GRCE Grace Therapeutics, Inc. | 10% Owner | Buy | 14,632 | $2.03 | $29,682.81 | +0.5% | |
| Oct 5, 2026 | GRCE Grace Therapeutics, Inc. | 10% Owner | Buy | 60,490 | $2.05 | $123,819.14 | +2.2% | |
| Oct 1, 2026 | ACOG Alpha Cognition Inc. | 10% Owner | Buy | 19,050 | $8.69 | $165,634.03 | +0.6% | |
| Sep 29, 2026 | GRCE Grace Therapeutics, Inc. | 10% Owner | Buy | 7,849 | $2.09 | $16,404.41 | +0.3% | |
| Sep 25, 2026 | ACOG Alpha Cognition Inc. | 10% Owner | Buy | 31,763 | $8.53 | $270,800.30 | +1.0% | |
| Sep 23, 2026 | GRCE Grace Therapeutics, Inc. | 10% Owner | Buy | 15,089 | $2.10 | $31,686.90 | +0.5% | |
| Sep 16, 2026 | ACOG Alpha Cognition Inc. | 10% Owner | Buy | 123,918 | $8.57 | $1,062,505.62 | +4.1% | |
| Sep 11, 2026 | SLGL Sol-Gel Technologies Ltd. | 10% Owner | Buy | 3,124 | $66.39 | $207,398.53 | +0.6% | |
| Sep 9, 2026 | GRCE Grace Therapeutics, Inc. | 10% Owner | Buy | 15,229 | $2.09 | $31,895.66 | +0.6% |